https://www.mynewsdesk.com/se/angelini-pharma Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/angelini-pharma https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Tue, 23 Sep 2025 09:32:50 +0200 Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG105 , a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and Taiwan. https://www.mynewsdesk.com/se/angelini-pharma/pressreleases/angelini-pharma-signs-exclusive-option-agreement-with-sovargen-to-license-global-development-and-commercialization-rights-for-innovative-brain-health-asset-3406095?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/angelini-pharma/pressreleases/angelini-pharma-signs-exclusive-option-agreement-with-sovargen-to-license-global-development-and-commercialization-rights-for-innovative-brain-health-asset-3406095?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Arvelle Therapeutics